Cike Peng1,2, Hongda Chen3, Markus Wallwiener4,5, Caroline Modugno4,5, Katarina Cuk6,7, Dharanija Madhavan6,7, Andreas Trumpp8,9, Jörg Heil4, Frederik Marmé4, Juliane Nees4,5, Sabine Riethdorf10, Sarah Schott4, Christof Sohn4, Klaus Pantel10, Andreas Schneeweiss4,5, Rongxi Yang6,7,11, Barbara Burwinkel6,7,11. 1. Molecular Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany. c.peng@dkfz.de. 2. Molecular Biology of Breast Cancer, Department of Gynecology and Obstetrics, University of Heidelberg, Heidelberg, Germany. c.peng@dkfz.de. 3. Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany. 4. Department of Gynecology and Obstetrics, University of Heidelberg, Heidelberg, Germany. 5. National Center for Tumor Diseases, University of Heidelberg, Heidelberg, Germany. 6. Molecular Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany. 7. Molecular Biology of Breast Cancer, Department of Gynecology and Obstetrics, University of Heidelberg, Heidelberg, Germany. 8. Hi-STEM-Heidelberg Institute for Stem Cell Technology and Experimental Medicine, GmbH, Heidelberg, Germany. 9. Division of Stem Cells and Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany. 10. Department of Tumor Biology, University Hospital Hamburg-Eppendorf, Hamburg, Germany. 11. Molecular Biology of Breast Cancer, University Women's Clinic University Heidelberg, ImNeuenheimer Feld 440, 69120, Heidelberg, Germany.
Abstract
UNLABELLED: Metastasis is the main cause of death in breast cancer patients. The development of reliable and cost-effective biomarker to evaluate the prognosis of metastatic breast cancer (MBC) patients is of great importance. S100P is a member of S100 family and has been proved to be associated with metastasis establishment. METHODS: We investigated the plasma S100P levels in 60 healthy controls, 48 primary and 273 metastatic breast cancer patients. The MBC patients were followed-up for disease progression and death up to 3.5 years after recruitment. Radiographic response of MBC patients were also analyzed for investigation on treatment monitoring value of plasma S100P level. We found a robust association between high plasma S100P level (>7 ng/mL) and poor prognosis of metastatic breast cancer (MBC) patients (median progression-free survival time: 5.0 vs. 8.7 months, log-rank test p < 0.001; median overall survival time: 22.5 vs. 31.6 months, log-rank test p < 0.001). The plasma S100P level added additional prognostic relevance to the conventional prognostication model with clinicopathological factors and CTC enumeration. The plasma S100P level decreased significantly after treatment, while the reduction correlated with the radiographic response of the MBC patients. This finding indicates the value of plasma S100P in dynamic evaluation of treatment outcome. We hereby suggest plasma S100P level as a simple and cost-effective marker for the prognosis of metastatic breast cancer.
UNLABELLED: Metastasis is the main cause of death in breast cancerpatients. The development of reliable and cost-effective biomarker to evaluate the prognosis of metastatic breast cancer (MBC) patients is of great importance. S100P is a member of S100 family and has been proved to be associated with metastasis establishment. METHODS: We investigated the plasma S100P levels in 60 healthy controls, 48 primary and 273 metastatic breast cancerpatients. The MBCpatients were followed-up for disease progression and death up to 3.5 years after recruitment. Radiographic response of MBCpatients were also analyzed for investigation on treatment monitoring value of plasma S100P level. We found a robust association between high plasma S100P level (>7 ng/mL) and poor prognosis of metastatic breast cancer (MBC) patients (median progression-free survival time: 5.0 vs. 8.7 months, log-rank test p < 0.001; median overall survival time: 22.5 vs. 31.6 months, log-rank test p < 0.001). The plasma S100P level added additional prognostic relevance to the conventional prognostication model with clinicopathological factors and CTC enumeration. The plasma S100P level decreased significantly after treatment, while the reduction correlated with the radiographic response of the MBCpatients. This finding indicates the value of plasma S100P in dynamic evaluation of treatment outcome. We hereby suggest plasma S100P level as a simple and cost-effective marker for the prognosis of metastatic breast cancer.
Entities:
Keywords:
Biomarker; Metastatic breast cancer; Plasma; Prognosis; S100P
Authors: Cigdem Selli; Arran K Turnbull; Dominic A Pearce; Ang Li; Anu Fernando; Jimi Wills; Lorna Renshaw; Jeremy S Thomas; J Michael Dixon; Andrew H Sims Journal: Breast Cancer Res Date: 2019-01-07 Impact factor: 6.466